Clarivate PLC Update Call Transcript
This document provides the transcript of an update call for Clarivate PLC (NYSE:CLVT) held on July 6, 2026, at 01:00 PM GMT. The call was led by Mark Donahue and included a Q&A session. The article also lists various past earnings call transcripts and conference appearances for Clarivate PLC, along with financial data like market cap, enterprise value, and stock performance.
Clarivate to Sell Life Sciences & Healthcare Segment to Altaris for $600 Million
Clarivate Plc (NYSE: CLVT) has announced a definitive agreement to sell its Life Sciences & Healthcare business to Altaris, a healthcare investment firm, for $600 million. This strategic move aims to simplify Clarivate's structure and focus on its core intellectual property and scientific research businesses. The transaction is expected to close in the second half of 2024.
Clarivate (NYSE: CLVT) to divest Life Sciences & Healthcare arm for $600M
Clarivate Plc has announced an agreement to sell its Life Sciences & Healthcare business to an affiliate of Altaris, LLC for a total consideration of $600 million. The payment includes $500 million cash at closing, a $25 million deferred payment, and a $75 million unsecured senior note. The transaction is expected to close by the end of 2026, subject to regulatory approvals and customary closing conditions.
Clarivate to sell Life Sciences & Healthcare for $600M, to use proceeds to reduce debt
Clarivate announced its agreement to sell its Life Sciences & Healthcare segment to Altaris for $600 million. The company plans to use the cash proceeds, approximately $525 million, to reduce debt and focus more on its Academia & Government and Intellectual Property segments. The transaction is expected to close by year-end 2026, and Clarivate has reaffirmed its full-year 2026 guidance.
Clarivate (CLVT) Sells Life Sciences Division for $600 Million
Clarivate PLC (CLVT) has sold its Life Sciences & Healthcare division to Altaris for $600 million, comprising $500 million cash upfront, a $25 million deferred payment, and a $75 million seller note. This strategic divestiture aims to help Clarivate focus on subscription-driven intelligence solutions for Academia & Government and Intellectual Property sectors and reduce its debt. Despite potential for a turnaround, concerns remain regarding its low GF Score™ of 44/100, particularly its financial strength.
Clarivate to sell life sciences unit for $600 million
Clarivate Plc announced it will sell its Life Sciences & Healthcare segment to Altaris LLC for $600 million. The company plans to use the $500 million cash proceeds to reduce its $4.34 billion debt. Following the transaction, Clarivate will focus on its Academia & Government and Intellectual Property segments and reaffirmed its full-year 2026 financial outlook, which includes the divested segment's results until the close.
Clarivate jumps 16% on $600M sale of life sciences segment
Clarivate Plc's shares surged 16% after the company announced the sale of its intellectual property (IP) and standards business (CPA Global and MarkMonitor brands) to government-backed investment firm Astorg and private equity firm Nordic Capital for $600 million. The company plans to use the proceeds to reduce its debt, which stood at $4.7 billion as of March 31. This divestiture is part of Clarivate's strategy to streamline its portfolio and reduce leverage.
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million
Clarivate Plc announced the sale of its Life Sciences & Healthcare (LS&H) segment to Altaris LLC for $600 million, sharpening its focus on its Academia & Government and Intellectual Property segments. The transaction is expected to enhance Clarivate's financial profile by improving revenue mix, expanding Adjusted EBITDA margin, and lowering capital intensity, with proceeds used to reduce debt. Clarivate reaffirmed its full-year 2026 financial outlook, including the LS&H segment results before its reclassification as discontinued operations.
Clarivate (NYSE: CLVT) divests LS&H unit for $600M to cut debt and lift margins
Clarivate Plc announced the sale of its Life Sciences & Healthcare (LS&H) segment to Altaris for $600 million, comprising $500 million cash at closing and a $75 million seller note, to sharpen its focus on Academia & Government and Intellectual Property businesses. The company plans to use the proceeds to reduce debt and improve its financial profile by increasing recurring revenue mix, boosting Adjusted EBITDA margin, and lowering capital intensity. Clarivate reaffirmed its full-year 2026 financial outlook, noting an expected non-cash goodwill impairment of $225–$250 million related to the divestiture.
CLVT - Clarivate Plc Dividends
This article provides detailed financial data and metrics for Clarivate Plc (CLVT), including its recent stock performance, valuation ratios, earnings per share, and institutional ownership. It highlights the company's dividend status (currently no dividend), market capitalization, and various profitability and efficiency ratios. The data also covers short interest, analyst recommendations, and historical price performance across different periods.
Clarivate (CLVT) Launches IPOne AI-Powered Intelligence Platform for IP Workflows
Clarivate (CLVT) has introduced IPOne, an AI-powered intelligence platform designed to streamline intellectual property workflows. Developed in collaboration with corporate IP teams and law firms, IPOne integrates AI agents with proprietary data to support tasks like patent discovery, trademark clearance, and litigation analysis. The platform also features Model Context Protocols (MCPs) for secure integration with enterprise AI tools, helping organizations maximize their IP assets' value and ensure transparent, internally controlled AI-driven decisions.
Clarivate (CLVT) director Snyder takes share retainer and reports tax withholding
Clarivate PLC director Andrew Miles Snyder reported receiving a quarterly award of 23,726 ordinary shares in lieu of a cash retainer for Board service, valued at $51,250 based on the June 30, 2026 closing price of $2.16 per share. The filing also indicated that 1,513 shares were withheld to cover tax obligations related to this award. Following these transactions, Snyder directly holds 294,429 ordinary shares, with additional indirect holdings through family trusts and Cambridge Information Group entities.
Clarivate (CLVT) director takes $28,750 retainer in shares, withholds stock for taxes
Clarivate Plc director Jane L Okun Bomba received 13,310 Ordinary Shares as a quarterly equity award, valued at $28,750, in lieu of a cash retainer for her Board service. On the same date, 386 shares were withheld to cover tax obligations, categorized as a tax-withholding disposition rather than an open-market sale. Following these transactions, Bomba directly holds 312,987 Ordinary Shares and indirectly holds 49,750 Ordinary Shares through a trust.
13,310-share award for Clarivate (CLVT) director, 2,662 withheld for tax
Clarivate director Kenneth L. Cornick received an award of 13,310 Ordinary Shares as compensation for his board service, elected in lieu of a $28,750 cash retainer. The shares were valued at $2.16 each. Following this, 2,662 shares were withheld for tax obligations, a non-market disposition. This transaction updates his direct holdings to 115,348 shares and indirect holdings through Cornick Family Investor, LLC to 1,100,000 shares, representing an administrative update rather than a directional market signal.
Saluting the team behind BioWorld's haul of seven APEX Awards
BioWorld has been honored with seven 2026 APEX Awards for Publication Excellence, including three Grand Awards and four Awards of Excellence, recognizing its commitment to journalistic integrity and comprehensive coverage of the global life sciences industry. These awards celebrate the team's exceptional reporting, writing, visual storytelling, and editorial collaboration, reaffirming BioWorld's mission to deliver trusted journalism and expert analysis to its readers for over 35 years. The honorees include Jennifer Boggs, Annette Boyle, Anette Breindl, Karen Carey, Marian (YoonJee) Chu, Ann Marie Griffith, Lee Landenberger, Harini Mathavan, Nuala Moran, Randy Osborne, Tamra Sami, Mari Serebrov, Amanda Lanier, and Mar de Miguel.
Clarivate (CLVT) Index Shift Sparks Questions About Its Evolving Investor Base And Valuation Story
Clarivate (CLVT) was moved from the Russell 1000 to the Russell 2000 indices, a shift that could alter its trading volumes, liquidity, and shareholder base for passive and quant investors. The article emphasizes that despite this index change, Clarivate's core investment narrative still hinges on the successful execution of its AI-driven, subscription-based products, like the recently launched Web of Science Research Intelligence, and its ability to manage its debt load. Investors need to evaluate how these factors will impact Clarivate's projected revenue and earnings growth and its valuation story.
Introducing EndNote Fusion: Advancing the next generation of reference management
Clarivate is launching EndNote Fusion, a new cloud-based platform that unifies EndNote and RefWorks capabilities to advance reference management for researchers. This new platform aims to seamlessly connect discovery, analysis, and writing, with RefWorks transitioning to EndNote Fusion later this year without disrupting existing data or workflows. For EndNote Desktop users, EndNote Fusion will offer optional cloud-based features, emphasizing continuity and flexibility while supporting diverse institutional needs and future innovation in reference management.
UPC opt-out and opt-in strategy: what the data shows
This article examines the evolving strategy of patent owners regarding the Unified Patent Court (UPC) jurisdiction, specifically focusing on the "opt-out then opt-in" approach. Data analysis reveals that a significant number of patent holders initially opt out of UPC jurisdiction to mitigate central revocation risk and later opt back in to pursue infringement actions on their terms. This two-step strategy is particularly prevalent in high-stakes technical fields such as drugs, medical devices, and electric communication technologies, indicating a maturing and sophisticated approach to patent enforcement under the UPC framework.
Clarivate Plc(NYSE: CLVT) added to Russell 2000 Index
Clarivate Plc (NYSE: CLVT), a provider of transformative intelligence solutions, has been added to the Russell 2000 Index. The article also provides an overview of Clarivate's business, including its three segments: Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Additionally, it lists recent news and financial data for the company.
Clarivate Plc(NYSE: CLVT) added to Russell 2000 Value Benchmark
Clarivate Plc (NYSE: CLVT) has been added to the Russell 2000 Value Benchmark. This inclusion is notable for the professional information services company, which specializes in solutions for academia, government, intellectual property, and life sciences. The article also provides recent news and financial data for Clarivate.
Clarivate Plc(NYSE: CLVT) dropped from Russell 1000 Value Benchmark
Clarivate Plc (NYSE: CLVT) has been removed from the Russell 1000 Value Benchmark. The company, which provides transformative intelligence solutions across Academia & Government, Intellectual Property, and Life Sciences & Healthcare segments, recently reaffirmed its 2026 outlook. Clarivate's stock closed at $2.130 USD with a recent 5-day change of +7.58%.
Price to book forward of Clarivate Plc – NYSE:CLVT
This page provides financial data for Clarivate Plc (NYSE: CLVT), specifically focusing on its price-to-book forward metric. The content is presented within the context of the TradingView platform, an interface for market data and analysis. While specific values are not displayed in the provided text, the page is dedicated to showing this particular financial indicator for Clarivate Plc.
CLVT Stock Holds Support As AI-Powered IP Push Accelerates
Clarivate Plc (CLVT) stock increased by 8.08% due to optimism surrounding its AI-powered IPOne platform and strategic growth initiatives. The company's focus on integrating AI into IP workflows, reinforcing its gatekeeper role in research metrics, and strong ESG performance are key drivers, even as it navigates a substantial debt load and aims to prove its "Value Creation Plan" to the market.
Price to sales forward of Clarivate Plc – NYSE:CLVT
The article focuses on the "Price to sales forward" metric for Clarivate Plc (NYSE: CLVT), a financial data point often used by investors to assess a company's valuation. While the article title highlights this specific financial ratio, the body content primarily consists of navigation and generic market data disclaimers without presenting the actual "Period," "Value," "Change," or "Change %" for the Price to sales forward of Clarivate Plc. It appears to be a stub or a placeholder page within a financial data platform.
Clarivate PLC Actuals & Estimates (FWB:16A)
This article provides financial actuals and analyst estimates for Clarivate PLC (FWB:16A), covering its income statement, balance sheet, cash flow, and valuation metrics. It includes information on the stock's maximum and minimum price estimates, historical highs and lows, and upcoming earnings report scheduled for August 11, 2026. The report also details past earnings and revenue performance, net income, employee count, and EBITDA.
16A Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Clarivate PLC (16A) stock on the Hannover Stock Exchange. It includes analyst ratings, future price predictions, and details on historical highs and lows, earnings, revenue, net income, and employee numbers. The information is presented for investors to conduct their own research.
Enterprise value to EBITDA forward of Clarivate Plc – NYSE:CLVT
This article provides financial data for Clarivate Plc (NYSE: CLVT), specifically its enterprise value to EBITDA forward. The content appears to be a snapshot of financial metrics from TradingView, indicating the company's valuation based on future earnings before interest, taxes, depreciation, and amortization.
Price to sales forward of Clarivate PLC – DUS:16A
This article provides a listing for Clarivate PLC (DUS:16A) on the Dusseldorf Stock Exchange, focusing on its financial metric "Price to sales forward." The content is part of a trading/financial platform, indicating no current trades and directing users to various financial tools and community features. It includes general information about the company's presence on the stock market.
From insights to decisions: What research institutions need from research intelligence
Research institutions face increasing pressure to diversify funding, enhance reputation, demonstrate societal impact, and make data-driven decisions with limited resources. This article highlights how Web of Science Research Intelligence helps address these challenges by providing connected workflows, trusted data, and responsible AI to synthesize information, scale insights, and responsibly assess societal impact. Institutions need tools that enable them to move beyond raw data to actionable insights and make confident strategic decisions.
Oncology consulting services to speed the path to approval
Clarivate's R&D Consulting services aim to accelerate the development and approval of oncology medicines by providing integrated, evidence-led decision-making across the drug development lifecycle. Their services address complex challenges such as shifting regulatory guidance, lead indication selection, and clinical endpoint optimization through expertise in discovery and translational sciences, industry benchmarking, clinical and regulatory consulting, and clinical outcomes assessment. The company emphasizes a patient-centric approach to ensure therapies reach those who need them faster.
Why meaningful patient engagement matters and how pharmas can accomplish it
The pharmaceutical industry is recognizing the critical importance of patient engagement in drug development and decision-making. This article outlines six core principles for effective patient-centered communication, emphasizing the need to focus on patient concerns, translate complex information clearly, use inclusive language, be transparent about risks, choose appropriate formats, and iterate based on patient feedback. By adopting these principles, pharmaceutical companies can build trust, enhance understanding, and empower patients to make informed decisions about their care.
Agentic AI, human expertise and the life sciences
The article discusses how agentic AI is poised to transform life sciences consulting by embodying accumulated knowledge, accessing vast data, and applying structured methodologies. It emphasizes that while AI can amplify human experts, the "irreplaceable human" is crucial for encoding knowledge into AI skills, validating data, and continuously refining AI agents. The future of life sciences consulting will be a hybrid model where human intelligence is augmented by AI to tackle complex challenges more efficiently.
Clarivate Releases 2025 Sustainability Report
Clarivate Plc has released its 2025 Sustainability Report, demonstrating continued progress toward its sustainability goals. The report highlights a significant 24% reduction in total reported greenhouse gas emissions. This update was announced on June 23, 2026, from London, showcasing the company's commitment to environmental responsibility.
Clarivate's Green Ledger: Data Giant Cuts Emissions by 24%
Clarivate Plc announced a 24% reduction in total greenhouse gas emissions, significantly progressing towards its Net Zero 2040 commitment. The reduction spans Scope 1, 2, and 3 emissions, demonstrating a comprehensive approach to sustainability, with 38% of office space now sustainability-certified. The company is also leveraging its data expertise for social impact through initiatives like antimicrobial stewardship and ProQuest One Sustainability.
Clarivate Releases 2025 Sustainability Report
Clarivate Plc has released its 2025 Sustainability Report, detailing the company's continuous advancements toward its sustainability objectives. A significant achievement highlighted in the report is a 24% reduction in total reported greenhouse gas emissions. The report emphasizes Clarivate's commitment to transformative intelligence and environmental responsibility.
Clarivate says total greenhouse gas emissions fell 24% in 2025
Clarivate (NYSE: CLVT) released its 2025 Sustainability Report, announcing a 24% reduction in total reported greenhouse gas emissions across all scopes, decreasing from 96,666 tCO₂e in 2024 to 73,110 tCO₂e in 2025. The report also highlights other sustainability achievements, including 38% of workplaces being sustainability-certified, over 36,000 volunteer hours contributed by colleagues, and the adoption of ProQuest One Sustainability by more than 400 institutions. Clarivate continues to focus on climate change, workforce impact, responsible business conduct, and supply chain transparency as part of its evolving sustainability approach.
The E.U. Biotech Competitiveness Act: what it means for global pharma companies
The E.U. Biotech Act is a strategic response to Europe's declining competitiveness in life sciences, aiming to streamline clinical development, foster innovation through new mechanisms, and enhance incentives for investment. While it represents a significant effort to reposition Europe as a hub for biotech innovation and evidence generation, its success will largely depend on effective implementation and proactive engagement from industry leaders. The Act targets operational fragmentation and seeks to attract investment, but executives must actively participate to fully leverage its potential benefits.
Clarivate Plc (CLVT) Appoints Simon Webster as President of Intellectual Property Segment
Clarivate Plc (CLVT) has appointed Simon Webster as President of its Intellectual Property segment, effective June 10, replacing Maroun S. Mourad. Webster previously led CPA Global before its merger with Clarivate, bringing extensive experience to the role. The company reaffirmed its full-year 2026 outlook, expecting revenue between $2.30 billion and $2.42 billion and adjusted EPS of $0.70 to $0.80.
Mitsubishi Fuso Truck and Bus Corporation Selects Clarivate (CLVT) IPfolio for IP Management
Mitsubishi Fuso Truck and Bus Corporation has chosen Clarivate's IPfolio platform for its intellectual property management. This move aims to centralize the management of patents and trademarks in the cloud, improving operational efficiency and providing cross-functional visibility throughout the IP lifecycle. The implementation is part of Mitsubishi Fuso’s broader digital transformation strategy and is supported by Clarivate’s local teams in Japan.
Clarivate Releases Journal Citation Reports 2026
Clarivate Plc has released its 2026 Journal Citation Reports (JCR), building on existing enhancements for transparency and inclusivity in journal-level metrics. The report includes data for 22,643 journals across 254 categories, showing an expansion of global participation and diversification of research output, particularly from Mainland China and India. Clarivate emphasizes the importance of using its multidimensional indicators for journal evaluation rather than assessing individual researchers or articles, ensuring consistency and reliability for the global research community.
Journal Citation Reports 2026: Supporting transparent, responsible journal evaluation
The Journal Citation Reports (JCR) 2026 release is now available, delivering updated journal metrics and reinforcing transparent, consistent journal evaluation. This release builds on previous enhancements, such as expanding the Journal Impact Factor (JIF) to all Web of Science Core Collection journals and excluding retracted content citations. JCR 2026 continues to support responsible journal evaluation with metrics for over 22,000 journals, increased transparency of journal status, and a commitment to providing a stable, multidimensional view of journal performance.
Global research shift: 521 journals gain impact factor in 2026 JCR
Clarivate (NYSE: CLVT) has released its 2026 Journal Citation Reports, covering 22,643 journals across 254 categories and highlighting trends like increased global participation and rising Global South representation. A significant 521 journals received a Journal Impact Factor for the first time, with 58% originating outside the US and Western Europe. This edition emphasizes transparency, consistency, and responsible use of journal indicators, offering a comprehensive framework for evaluating journal influence in the evolving scholarly publishing landscape.
Clarivate (NYSE: CLVT) grants 396,825 shares to IP president
Clarivate PLC (NYSE: CLVT) has granted 396,825 Ordinary Shares to its President of Intellectual Property, Simon Webster, as compensation. This equity award, recorded at no cash cost per share, increases Webster's direct holdings to 4,626,325 Ordinary Shares. The transaction, filed as a Form 4, signifies an incremental increase in his existing stake and was not a sale.
Clarivate's IPfolio Selected by Mitsubishi Fuso
Clarivate Plc announced that Mitsubishi Fuso Truck and Bus Corporation has chosen IPfolio as its intellectual property (IP) management solution. This integration will provide Mitsubishi Fuso with a modern, scalable platform to manage patents, trademarks, and other IP information, thus enabling more efficient IP management, improved data accuracy, and faster decision-making. The partnership aims to enhance Mitsubishi Fuso's IP-driven digital transformation by streamlining processes and providing cross-functional visibility.
Mitsubishi Fuso selects Clarivate’s IPfolio for IP management By Investing.com
Mitsubishi Fuso Truck and Bus Corporation has chosen Clarivate's IPfolio platform for centralized intellectual property management, including patents and trademarks. The system integrates data synchronization, annuity, and renewal management. This selection deepens the partnership between the two companies, with Clarivate providing support through its Japan-based teams.
Truck maker Mitsubishi Fuso puts its patents in Clarivate’s cloud
Clarivate announced that Mitsubishi Fuso Truck and Bus Corporation has selected its IPfolio platform as its cloud-based intellectual property management solution. IPfolio, combined with Derwent patent data, will help Mitsubishi Fuso centralize, manage, and verify its patents, trademarks, and other IP information, aiming to streamline processes and improve decision-making. The implementation will be supported by Clarivate teams in Japan, allowing Mitsubishi Fuso to accelerate its IP digital transformation.
Clarivate's IPfolio Selected by Mitsubishi Fuso
Clarivate Plc announced that Mitsubishi Fuso Truck and Bus Corporation has selected IPfolio as its intellectual property management solution. IPfolio will provide Mitsubishi Fuso with a modern, scalable platform to manage IP, enhancing operational confidence, data accuracy, and decision-making processes. This implementation aims to accelerate Mitsubishi Fuso's IP digital transformation by centralizing patent, trademark, and other IP information, enabling cross-functional visibility and streamlined management.
Clarivate (NYSE: CLVT) President, IP reports 4,229,500 Ordinary Shares
Simon Webster, President, IP at Clarivate (NYSE: CLVT), has filed an initial Form 3, disclosing his beneficial ownership of 4,229,500 Ordinary Shares in the company. This filing serves as an initial statement of ownership and does not indicate any recent buying or selling activity. The shares are held directly as of June 10, 2026, establishing a baseline for his equity stake.
The five stages of pharma competitive intelligence workflows
This article outlines five crucial stages in pharma competitive intelligence (CI) workflows: finding, analyzing, generating insights, communicating, and scenario modeling. It emphasizes that while AI can accelerate the initial stages of data aggregation, the interpretive and strategic advisory aspects still depend heavily on human judgment, stakeholder communication, and robust, traceable data. The author argues that high-performing CI teams prioritize source traceability, define clear decision questions, include recommendations in deliverables, tailor communication formats to specific decisions, and actively engage in forward-looking scenario modeling to truly influence strategic decisions.
Clarivate shares jump 7% after earnings beat and outlook reaffirmed
NULL
